SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2026 / Cilt: 42 Sayı: 1

-

Premenopozal ve postmenopozal kadınlarda lipit profili ve plazma aterojenik indeksinin karşılaştırılması

Cennet Yıldız
Abdülmelik Yıldız
Fatih Tekiner
Pages
36–40
Publication Date
2015-05-09
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Atherogenic index of plasma which is a marker of plasma atherogenicity may be used to asses risk of developing atherosclerosis in postmenopausal women

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Menopause leads to changes in hormonal status, metabolism and lipid profile.
📊
Key Findings & Data:Methods: This study included 160 postmenopausal and 260 premenopausal healthy women.
💡
Conclusion & Impact:Atherogenic index of plasma which is a marker of plasma atherogenicity may be used to asses risk of developing atherosclerosis in postmenopausal women
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Menopoz · lipit profili · plazma aterojenik indeksi

Abstract

Objective: Menopause leads to changes in hormonal status, metabolism and lipid profile. The aim of the present study was to determine the influence of menopause and age on lipid profile in women. Methods: This study included 160 postmenopausal and 260 premenopausal healthy women. Serum lipid profile including total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and atherogenic index of plasma (AIP) were estimated. Premenopausal women were further arranged in to two different age group of 22-45 years and above 45 years of age. The premenopausal and postmenopausal women were recruited and classified using a comprehensive questionnaire. Results: There were statistically significant increases in TC, LDL-C, TG and AIP but there was no significant difference in HDL-C level between premenopausal and postmenopausal women. Only LDL-C level was significantly increased in premenopausal women above 45 years of age compared with the premenopausal women between 22-45 years of age. Conclusion: Menopause alters lipid profile. Atherogenic index of plasma which is a marker of plasma atherogenicity may be used to asses risk of developing atherosclerosis in postmenopausal women

Özet

Amaç: Menopoz ile birlikte hormonal durum, metabolizma ve lipit profilinde bir takım değişiklikler meydana gelir. Çalışmamızın amacı yaşın ve menopozun lipit profilinde meydana getirdiği değişiklikleri incelemektir. Yöntemler: Çalışmaya sağlıklı 160 postmenopozal ve 260 premenopozal kadın alındı. Tüm olgulara bir anket formu doldurtuldu. Tüm olguların total kolesterol (TK), yüksek yoğunluklu lipoprotein kolesterol (HDL-K), düşük yoğunluklu lipoprotein kolesterol (LDL-K), trigliserid (TG) ve plazma aterojenik indeksi (PAI) değerlendirildi. Premenopozal kadınlar ayrıca 22-45 yaş ile ve 45 yaş üzeri olmak üzere iki gruba ayrıldı. Bulgular: Menopoz sonrası kadınlarda TK, LDL-K, TG ve PAI değerleri anlamlı olarak yüksek bulunurken, HDL-K seviyesinde anlamlı fark saptanmadı. Kırk beş yaş üzeri premenopozal kadınlarda sadece LDL-K seviyesi anlamlı olarak yüksek bulundu. Sonuç: Menopoz lipit profilinde değişiklikler ile birliktedir. Plazma aterojenitesi için bir belirleyici olan PAI, postmenopozal kadınlarda ateroskleroz riski için kullanılabilir. Anahtar kelimeler: Menopoz, lipit profili, plazma aterojenik indeksi.

🔖

Cite This Article

Yıldız, C., Yıldız, A., Tekiner, F. (2015). -. Dicle Tıp Dergisi, Cilt: 42 Sayı: 1, 36–40. https://doi.org/10.5798/diclemedj.0921.2015.01.0526

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (106)

  1. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and
  2. the risk of coronary heart disease in women. N Engl J Med;316:1105-1110.
  3. Hsia J, Barad D, Margolis K, et al. Usefulness of prior hysterectomy
  4. as an independent predictor of Framingham
  5. risk score (The Women’s Health Initiative). Am J Cardiol;92:264 -269.
  6. Matthan MR, Jalbert SM, Lamon-Fava S, et al. TRL, IDL,
  7. and LDL Apolipoprotein B-100 and HDL Apolipoprotein
  8. A-I kinetics as a function of age and menopausal status.
  9. Arterioscler Thromb Vasc Biol 2005;25:1691-1696.
  10. National Cholesterol Education Program (NCEP) Expert Panel
  11. on Detection, Evaluation, and Treatment of High Blood
  12. Cholesterol in Adults (Adult Treatment Panel III). Third
  13. Report of the National Cholesterol Education Program
  14. (NCEP) Expert Panel on Detection, Evaluation, and Treatment
  15. of High Blood Cholesterol in Adults (Adult Treatment
  16. Panel III) final report. Circulation 2002;106:3143-3421.
  17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk
  18. factor to cardio vascular disease independent of high density
  19. lipoprotein cholesterol level: a meta-analysis of population
  20. based prospective studies. J Cardiovasc Risk 1996;:213-219.
  21. Guerin M, Legoff W, Lassel TS, et al. Proatherogenic role of
  22. elevated CE transfer from HDL to VLDL and dense LDL
  23. in type 2 diabetics. Arterioscler Thromb Vasc Biol 2001;:282-287.
  24. Dobiásová M, Frohlich J. The plasma parameter log (TG/
  25. HDL-C) as an atherogenic index: Correlation with lipoprotein
  26. particle size and esterification rate in apoB-lipoproteindepleted
  27. plasma (FER (HDL)). Clin Biochem 2001;34:583-
  28. Schiller NB, Shah PM, Crawford M, et al. Recommendations
  29. for quantitation of the left ventricle by two-dimensional
  30. echocardiography. American Society of Echocardiography
  31. Committee on Standards, Subcommittee on Quantitation of
  32. Two- Dimensional Echocardiograms. J Am Soc Echocardiogr;2:358-367.
  33. Xing D, Nozell S, Chen Y, et al. Estrogen and Mechanisms
  34. of Vascular Protection. Arterioscler Thromb Vasc Biol;29:289-295.
  35. Ramos RG, Olden K. The prevalence of metabolic syndrome
  36. among US women of childbearing age, Am J Public
  37. Health 2008;98:1122-1127.
  38. Wu ZY, Wu XK, Zhang YW. Relationship of menopausal
  39. status and sex hormones to serum lipids and blood pressure.
  40. Int J Epidemiol 1990;19: 297-302.
  41. Poehlman ET, Toth MJ, Ades PA, Rosen CJ. Menopauseassociated
  42. changes in plasma lipids, insulin-like growth
  43. factor I and blood pressure: a longitudinal study. Eur J Clin
  44. Invest 1997;27:322-326.
  45. Stevenson JC, Crook D, Godsland IF. Influence of age and
  46. menopause on serum lipids and lipoproteins in healthy
  47. women. Atherosclerosis 1993; 98:83-90.
  48. Matthews KA, Meilahn E, Kuller LH, et al. Menopause
  49. and risk factors for coronary heart disease. N Engl J Med.;321:641- 646.
  50. Davis CE, Pajak A, Rywik S, et al. Natural menopause and
  51. cardiovascular disease risk factors. The Poland and US Collaborative Study on Cardiovascular Disease Epidemiology.
  52. Ann Epidemiol 1994;4:445-448.
  53. Brown SA, Hutchinson R, Morrisett J, et al. Plasma lipid,
  54. lipoprotein cholesterol, and apoprotein distributions in selected
  55. US communities. The Atherosclerosis Risk in Communities
  56. (ARIC) Study. Arterioscler Thromb 1993;13:1139-1158.
  57. Demirovic J, Sprafka JM, Folsom AR, et al. Menopause
  58. and serum cholesterol: differences between blacks and
  59. whites. The Minnesota Heart Survey. Am J Epidemiol;136:155-164.
  60. Bonithon-Kopp C, Scarabin PY, Darne B, et al. Menopauserelated
  61. changes in lipoproteins and some other cardiovascular
  62. risk factors. Int J Epidemiol 1990;19:42-48.
  63. The writing group for the PEPI trial. Effects of estrogen or
  64. estrogen/progestin regimens on heart disease risk factors in
  65. postmenopausal women. JAMA 1995;273:199-208.
  66. Rosano GM, Fini M. Postmenopausal women and cardiovascular
  67. risk: impact of hormone replacement therapy. Cardiol
  68. Rev 2002;10:51-60.
  69. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and
  70. the risk of coronary heart disease: 10,158 incident cases
  71. among 262,525 participants in 29 Western prospective
  72. studies. Circulation 2007;115:450-458.
  73. Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as
  74. a risk factor for cardiovascular diseases in the Asia-Pacific
  75. region. Circulation 2004;110:2678-2686.
  76. da Luz PL, Favarato D, Faria-Neto JR Jr, et al. Highratio of
  77. triglycerides to HDL-cholesterol predicts extensive coronary
  78. disease. Clinics (Sao Paulo) 2008;63:427-432.
  79. Gaziano JM, Henne kens CH, O.Donnell CJ, et al. Fasting
  80. triglycerides, high density lipoprotein, and risk of myocardial
  81. infarction. Circulation 1997;96:2520-2525.
  82. Nwagha UI, Ikekpeazu EJ, Ejezie FE, et al. Atherogenic
  83. index of plasma as useful predictor of cardiovascular risk
  84. among postmenopausal women in Enugu, Nigeria. Afr
  85. Health Sci 2010;10:248-252.
  86. Söğüt E, Avcı E, Üstüner F, Arıkan E. Serum aterojenite indeksi
  87. olarak (TG/HDL-K) oranının değerlendirilmesi. Türk
  88. Klinik Biyokimya Derg 2006; 4:1-8.
  89. Usoro CAO, Adikwuru CC, Usoro IN, Nsonwu AC. Lipid
  90. profile of postmenopausal women in Calabar, Nigeria. Pak
  91. J Nutr 2006;5:79-82.
  92. Haarbo J, Hassager C, Schlemmer A, Christianson C, Influence
  93. of smoking, body fat distribution and alcohol consumption
  94. on serum lipids, lipoproteins and apolipoproteins
  95. in early postmenopausal women, Atherosclerosis, 1990;84:
  96. Onat A. Lipids, Lipoproteins and apolipoproteins among
  97. Turks, and impact on coronary heart disease - Invited Review.
  98. Anadolu Kardiyol Derg 2004;4:236-245.
  99. Kozan Ö, Oğuz A, Abacı A, et al. Prevalence of the metabolic
  100. syndrome among Turkish adults. Eur J Clin Nutr;61:548-553.
  101. Açık Y, Sezer E, Sezer H. Frequency and distribution of
  102. risk factors for coronary heart disease in the adult population
  103. of rural district of Elazıg Turkey. Turk J Med Sci;29:265-272.
  104. Igweh JC, Nwagha IU, Okaro JM. The effects of menopause
  105. on the serum lipid profile of normal females of South
  106. East Nigeria. Nigerian J Physiol Sci 2005;20:48-53.